Mobile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitoste...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-001580-22

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

In patients with sitosterolemia who have been taking ezetimibe 10 mg daily for at least 6 months prior to entry, to compare the effects of adding ezetimibe 30 mg versus placebo to ongoing ezetimibe 10-mg treatment for 26 weeks on plasma sitosterol concentration.

Critère d'inclusion

  • Homozygous Sitosterolemia

Liens